Podcasts about Acute myeloid leukemia

Jennifer Vertentes was a police officer in Providence Rhode Island when she decided to go to Hasbro Children's Hospital on Thanksgiving Day of 2018 to meet kids who had to spend their Thanksgiving being treated for different reasons, including being treated for Pediatric Cancer. While she was there she met 3 year old Emerson Lucier who was going through her 3rd battle with Acute Myeloid Leukemia . This meeting inspired Jennifer to start her HERO PACKAGE FOUNDATION to help put a smile on the faces of these kids who were battling these difficult diseases. Jennifer, who in 2023 had to retire from the Police Department after suffering an injury while trying to save a person who was drowning, was also diagnosed with Ovarian Cancer that year. Fortunately for the Pediatric Cancer community, she continues to help these kids as she deals with her disease, that fortunately was diagnosed at a very early stage. 

Kelsey Lauria began to have massive headaches early in the fall of her senior year in high school in 2014 which led to her diagnosis of Acute Myeloid Leukemia. In the later part of the winter in 2015, Kelsey experienced heart failure which led to her passing on April 18th, just 6 days after her 18th birthday and less than 6 months after her cancer diagnosis. During her treatment, Kelsey started her Bald Beauties Project to help in the fight against Pediatric Cancer and this successful non-profit has been run by her mom Maya since Kelsey's passing. 

Imagine the shock and horror of having a child be diagnosed with Acute Myeloid Leukemia, going through treatment for that for 8 months,, relapsing 2 months later, and then being told that the first diagnosis was wrong, and that the child actually had  Ewings Sarcoma. That is what happened to then 2 1/2 year old Connor Mocey who is now 5 years old and doing as well as possible while dealing with this difficult Bone Cancer. 

In this week's episode, we'll learn more about how measurable residual disease might help guide decisions about post-transplant gilteritinib maintenance in FLT3-ITD acute myeloid leukemia, or AML; how stemness contributes to chemotherapy resistance in AML; and effects of babesiosis on red blood cells from individuals with sickle cell disease, sickle cell trait, and wild-type hemoglobin. Featured Articles:Measurable residual disease and post-transplantation gilteritinib maintenance for patients with FLT3-ITD-mutated AML GATA2 links stemness to chemotherapy resistance in acute myeloid leukemia Babesiosis and Sickle Red Blood Cells: Loss of Deformability, Heightened Osmotic fragility and Hyper-vesiculation 

In this week's episode we'll learn more about how phosphoseryl-tRNA kinase inhibition promotes cell death in acute myeloid leukemia, or AML; APOE gene variants and their association with post-hematopoietic stem cell transplant outcomes in AML; and pathways by which chronic inflammation and oxidative stress may lead to cardiomyopathy in patients with sickle cell disease.Featured Articles:PSTK inhibition activates cGAS-STING, precipitating ferroptotic cell death in leukemic stem cells Common Hereditary Variants of the APOE Gene and Posttransplant Outcome in Acute Myeloid Leukemia 17R-Resolvin D1 Protects Against Sickle Cell Related Inflammatory Cardiomyopathy in Humanized Mice 

Dr. John Sweetenham and Dr. James Foran discuss the evolving treatment landscape in acute myeloid leukemia, including new targeted therapies, advances in immunotherapy, and the current role for allogeneic transplantation. TRANSCRIPT Dr. John Sweetenham: Hello, I'm Dr. John Sweetenham, the host of the ASCO Daily News Podcast. There has been steady progress in the therapies for acute myeloid leukemia (AML) in recent years, largely based on an increasing understanding of the molecular mechanisms which underlie the disease. On today's episode, we'll be discussing the evolving treatment landscape in AML. We'll explore risk group stratification, new targeted therapies, advances in immunotherapy for AML, and also a little about the current role for allogenic transplantation in this disease.  I'm delighted to welcome Dr. James Foran to this discussion. Dr. Foran is a professor of medicine and chair of the Myeloid Malignancies and Blood and Marrow Transplant Disease Group at the Mayo Clinic Comprehensive Cancer Center. He's based in Jacksonville, Florida.  Our full disclosures are available in the transcript of this episode.  James, it's great to have you join us on the podcast today, and thanks so much for being here. Dr. James Foran: I'm delighted and thank you for the invitation. Thank you very much. Dr. John Sweetenham: Sure, James, let's get right into it. So, our understanding of the molecular mechanisms underlying AML has resulted not only in new methods for risk stratification in this disease, which have added refinement to cytogenetics, but also has resulted in the development of many new targeted agents. Understanding that this is a complex area of investigation, and our time is somewhat limited, can you give us a high-level update on the current state of the art in terms of how risk factors are being used for treatment selection now? Dr. James Foran: Absolutely. I think in the past, you know, we had things broken down pretty simply into make a diagnosis based on morphology, do cytogenetics, break patients into the groups of those who were more likely to benefit from therapy – so-called favorable risk – those where the intensive therapies were less likely to work – so-called poor adverse risk, and then this large intermediate group that really had variable outcomes, some better, some worse. And for a long time, the progress was in just identifying new subtle cytogenetic risk groups. And then, late 1990s, we began to understand that FLT3 mutations or NRAS mutations may be more adverse than others that came along. In the first part of this millennium, in the, you know, 2000-2010 range, a lot of work was being done to understand better or worse risk factors with single genes. The ability to do multiplex PCR, and then more recently NGS platforms, have allowed us to really look at many genes and identify many mutations in patients. At the beginning that was used just to sort of refine – who did a little better, who did a little worse with intensive therapy – helped us decide who may benefit more from an allogeneic transplanter for whom that would not be necessary.  But the good news is that really, we're now starting to target those mutations. One of the first molecularly targeted treatments in leukemia was FLT3 mutations, where we knew they were adverse. Then along came targeted treatments. I was involved in some of those early studies looking at sunitinib, sorafenib, more recently midostaurin, now quizartinib, FDA approved, and gilteritinib in the relapse refractory setting.  So we're moving into a state where we're not just refining prognosis, we're identifying targets. You know, it's been slow progress, but definite incremental progress in terms of outcomes by looking for FLT3 mutations, then looking for IDH mutations, and more recently, mutations involving NPM1 or rearrangement of what we used to call the MLL gene, now the lysine methyltransferase 2A or KMT2A rearrangement, where we now have targets. And it's not just for refinement of prognosis, but now we're identifying therapeutic targets for patients and ways to even look for measurable residual disease which is impacting our care. Dr. John Sweetenham: That's great, James. And I'm going to expand on that theme just a little bit and perhaps ask you to elaborate a little bit more on how the introduction of these new therapies have specifically impacted frontline therapy. And a couple of ancillary questions maybe to go along with that: First of all, is ‘7+3' a standard therapy for anybody in 2025? And maybe secondly, you know, could you comment also maybe briefly on older patients with AML and how you think maybe the treatment landscape is changing for them compared with, say, 5 or 10 years ago? Dr. James Foran: I'll start with the therapy and then work my way back. So we've had ‘7+3' cytarabine daunorubicin or cytarabine anthracycline since 1976, and we're still using it as the backbone of our intensive therapy. There is still an important role for it, particularly in younger or fitter patients, and particularly for those with intermediate or favorable risk genetic groups or cytogenetic risk groups just because we achieve high rates of remission. Our 30-day induction mortality rates are lower now than they were 10 and 20 years ago. Our supportive care is better. And we still have a busy inpatient hospital service here at Mayo Florida and my colleagues in Rochester and Arizona as well giving intensive therapy. So that remains the backbone of curative therapy for younger adults. We are trying to be a little more discriminating about who we administer that to. We are trying to add targeted agents. We know from, now, two different randomized trials that the addition of a FLT3 inhibitor, either midostaurin or more recently quizartinib, has a survival advantage in patients with a FLT3 mutation, or for quizartinib, a FLT3/ITD mutation. And so yes, ‘7+3' remains important.  Off protocol for somebody who just comes in with acute leukemia in a 40-year-old or 30-year-old or even early 60s and fit, we would still be considering ‘7+3' therapy and then waiting for an expedited gene mutation panel and an expedited cytogenetics panel to come back to help us discriminate is that a patient for whom we should be giving a FLT3 inhibitor? I think there's a little more nuance about when we do a day 14 bone marrow, do they really matter as much anymore? I still do them. Some of my colleagues find them less important. But we're still giving intensive therapy. We're still giving high-dose ARA-C consolidation for younger patients who achieve complete remission.  In older adults, it's a different story. You know, it was only in the early part of the 2000s – 2004, 2007 range – where we really got buy-in from randomized studies that low-dose therapy was better than no therapy. There was a lot of nihilism before then about therapy for older adults, especially over age 75. We know that low-dose ARA-C is better than nothing. It looked like azacitidine was better than ARA-C or at least equivalent or slightly better. But with the advent of venetoclax it was a game changer. I ran a national randomized study of intensive therapy in AML. It was the last national randomized study of intensive therapy in older patients right before venetoclax got approved. And we were very excited about our results, and we thought we had some really interesting clinical results. And suddenly that's a little bit obsolete in patients over 70 and particularly over age 75 because of the high remission rates with azacytidine venetoclax or hypomethylating agents, so-called HMAs and venetoclax and the survival advantage. Now, it's not a home run for everybody. We quote 60% to 70% remission rates, but it's a little different based on your cytogenetics and your mutation profile. You have to continue on therapy so it's continuous treatment. It's not with curative intent, although there are some people with long-term remission in it. And the median survival went from 10 months to 15 months. So home run? No, but definitely improved remissions, meaningful for patients off transfusions and better survival. So right now it's hard to find an older adult who you wouldn't give azacitidine and venetoclax or something similar, decitabine, for instance, and venetoclax, unless somebody really was moribund or had very poor performance status or some reason not to. And so ‘7+3' is still relevant in younger adults. We're trying to get better results with ‘7+3' by adding targeted agents and azacitine and venetoclax in older adults.  I think the area of controversy, I guess there are two of them, is what to do in that overlap age between 60 and 75. Should people in that age still get intensive therapy, which we've used for years – the VIALE-A trial of aza-venetoclax was age 75 plus – or with cardiac comorbidities? And I think if you're 68 or 72, many of us are starting to bias towards aza-venetoclax as generally being better tolerated, generally being more outpatient, generally being slow and steady way to get a remission. And it doesn't stop you from going to transplant for somebody who might still be a candidate.  The other area of controversy is somebody under 60 who has adverse cytogenetics where we don't do very well with ‘7+3,' we still give it and we might do just as well with decitabine venetoclax. A lot of us feel that there's equipoise in the 60 to 75 group where we really can ask a question of a randomized study. Retrospective studies might suggest that intensive therapy is a little better, but there are now a couple of randomized studies happening saying, “Can we replace ‘7+3' in that intermediate age with aza-venetoclax?” And for younger adults similarly, we're looking to see how we apply that technology. Those are the areas where we're really trying to investigate what's optimal for patients and that's going to require randomized trials. Dr. John Sweetenham: Oh, that's great, thank you. And I'll just extend that question a little bit more, particularly with respect to the new targeted therapies. How much are they impacting the treatment of these patients in the relapse and refractory setting now? Dr. James Foran: Oh, they're definitely impacting it. When I trained and probably when you trained, AML was still a medical emergency. But that was the thing that you admitted to the hospital immediately, you started therapy immediately. The rule was always that's the one thing that brings the fellow and the consultant in at night to see that new patient on a Friday or Saturday. Now, we'll still admit a patient for monitoring, but we try not to start therapy for the first three or five or seven days if they're stable, until we get those genetics and those genomics back, because it helps us discriminate what therapy to pursue. And certainly, with FLT3 mutations, especially FLT3/ITD mutations, we're adding FLT3 inhibitors and we're seeing a survival advantage. Now, on the surface, that survival advantage is in the range of 7% or 10%. But if you then pursue an allogeneic transplant in first remission, you're taking disease where we used to see 30%, 40% long-term survival, maybe less, and you're pushing that to 60%, 70% in some studies. And so we're now taking a disease that– I don't want to get off topic and talk about Ph+ ALL. But that's a disease where we're actually a little excited. We have a target now, and it used to be something really adverse and now we can do a lot for it and a lot about it.  The other mutations, it's a little more subtle. Now, who knew until 2010 that a mutation in a sugar metabolism gene, in isocitrate dehydrogenase, or IDH was going to be so important, or even that it existed. We know that IDH1 and IDH2 mutations are still a minority of AML, certainly less than 10% to 15%, maybe overall. But we're able to target those with specific IDH1 and IDH2 inhibitors. We get single-agent responses. There are now two approved IDH1 inhibitors on the market. We don't yet have the randomized data that adding those to intensive therapy is better, but we're getting a very strong hint that it might be better in older adults who have an IDH mutation, maybe adding those is helpful and maybe adding those to low-intensity therapy is helpful. Those studies are ongoing, and we're also trying with low-intensity treatments to add these agents and get higher remission rates, deeper remissions, longer remissions. I think a lot of work has to be done to delineate the safety of that and the long-term efficacy. But we're getting hints it's better, so I think it is impacting.  The other area it's impacting is when you pick up adverse mutations and those have crept into our classification systems like an ASXL1 mutation or RUNX1 mutation for instance, or some of the secondary AML mutations like BCOR and others, where that's helping us discriminate intermediate-risk patients who we think aren't going to do as well and really helping us select a group who's more likely to get benefit from allogeneic transplant or for whom at least our cure rates without allo transplant are low. And so I think it's impacting a lot. Dr. John Sweetenham: Great. And I'm going to pick up now, if I may, on a couple of things that you've just mentioned and continue the theme of the relapsed and refractory setting. We've started to see some reports which have looked at the role of immune strategies for patients with AML, in particular CAR T or NK cells. Can you comment a little on this and let us know whether you think either these two strategies or other immune strategies are likely to have a significant role in AML in the future? Dr. James Foran: They are, but I think we're still a step behind finding the right target or the right way to do it. If you think of allogeneic transplantation as the definitive immune therapy, and we know for adverse AML we can improve survival rates and cure rates with an allotransplant, then we know inherently that immune therapy matters. And so how do we do what they've done in large cell lymphoma or in CD19 targeting for B cell malignancies? How do we bring that to acute myeloid leukemia? There have been a number of efforts. There have been at least 50 trials looking at different targets. CD33, CD123, CD7, others, CLL-1. So, there have been a number of different trials looking at how to bind a CAR T or a CAR T construct that can be active. And we have hints of efficacy. There was kind of a provocative paper in the New England Journal of Medicine a year ago in April of last year from a Chinese group that looked at a CD7-based CAR T and it was 10 patients, but they used CD7 positive acute leukemia, AML or ALL and had a CD7-targeted CAR T and they actually incorporated that with a haploidentical transplant and they had really high remission rates. People tolerated it quite well. It was provocative. It hasn't yet been reproduced on a larger scale, but the strong hints that the strategy is going to work.  Now, CD33 is a little tricky to have a CAR T when CD33 is expressed on normal hematopoietic cells. CD123 likewise. That's been something where there's, I think, still promise, but we've struggled to find the trials that make that work. Right now, there's a lot of interest in leveraging NK cells and looking, for a couple of reasons, but NK cells are attractive and NK cell markers might be attractive targets. NK cells might have similar degrees of immune efficacy. It's speculative, but they are likely to have less cytokine release syndrome and less neurotoxicity than you see with CAR T. And so it's kind of attractive to leverage that. We have had some ongoing trials looking at it with bispecifics and there certainly are trials looking at it with CAR NK-based strategies. One of the antigens that people looked at is the NK group 2D. NK group 2D or NKG2D is overexpressed in AML and its ligands overexpressed. And so that's a particular potential target. So, John, it's happening and we're looking for the hints of efficacy that could then drive a pivotal trial to get something approved.  One of the other areas is not restricting yourself just to a single antigen. For instance, there is a compound that's looking at a multi-tumor-associated antigen-specific T-cell therapy, looking at multiple antigens in AML that could be overexpressed. And there were some hints of activity and efficacy and actually a new trial looking at a so-called multi-tumor associated antigen-specific T cell therapy. So without getting into specific conflicts of interest or trials, I do think that's an exciting area and an evolving area, but still an investigational area. I'll stop there and say that we're excited about it. A lot of work's going there, but I'm not quite sure which direction the field's going to pivot to there. I think that's going to take us some time to sort out. Dr. John Sweetenham: Yeah, absolutely. But as you say, exciting area and I guess continue to watch this space for now.  So you've mentioned allogeneic stem cell transplants two or three times during this discussion. Recognizing that we don't have an imatinib for AML, which has kind of pushed transplant a long way further back in the treatment algorithm, can you comment a little on, you know, whether you think the role of stem cell transplantation is changing in AML or whether it remains pretty much as it was maybe 10 years ago? Dr. James Foran: By the way, I love that you use imatinib as an introduction because that was 6 TKIs ago, and it tells you the evolution in CML and you know, now we're looking at myristoyl pocket as a target, and so on. That's a great way to sort of show you the evolution of the field.  Allogeneic transplant, it remains a core treatment for AML, and I think we're getting much smarter and much better about learning how to use it. And I'm just going to introduce the topic of measurable residual disease to tell you about that. So I am a little bit of a believer. Part of my job is I support our allogeneic transplant program, although my focus is acute myeloid leukemia, and I've trained in transplant and done it for years and did a transplant fellowship and all that. I'm much more interested in finding people who don't need a transplant than people who do. So I'm sort of looking for where can we move away from it. But it still has a core role. I'll sidestep and tell you there was an MDS trial that looked at intermediate or high-risk MDS and the role of allogeneic transplant that shows that you about double your survival. It was a BMT CTN trial published several years ago that showed you about double your three-year survival if you can find a donor within three months and get to a transplant within six months. And so it just tells you the value of allotransplant and myeloid malignancy in general. In AML we continue to use it for adverse risk disease – TP53 is its own category, I can talk about that separately – but adverse risk AML otherwise, or for patients who don't achieve a really good remission. And I still teach our fellows that an allotransplant decreases your risk of relapse by about 50%. That's still true, but you have to have a group of patients who are at high enough risk of relapse to merit the non-relapse mortality and the chronic graft versus host disease that comes with it. Now, our outcomes with transplant are better because we're better at preventing graft versus host disease with the newer strategies such as post-transplant cyclophosphamide. There are now new FDA-approved drugs for acute and chronic graft versus host disease, ruxolitinib, belumosudil, axatilimab now. So we have better ways of treating it, but we still want to be discriminating about who should get it.  And it's not just a single-minded one-size-fits-all. We learned from the MORPHO study that was published in the JCO last year that if you have FLIT3-positive AML, FLIT3/IDT-positive AML, where we would have said from retrospective studies that your post-transplant survival is 60% give or take, as opposed to 15% or 20% without it, that we can discriminate who should or shouldn't get a transplant. Now that trial was a little bit nuanced because it did not meet its primary endpoint, but it had an embedded randomization based upon MRD status and they used a very sensitive test of measurable residual disease. They used a commercial assay by Invivoscribe that could look at the presence of a FLT3/ITD in the level of 10 to the minus 5th or 10 to the minus 6th. And if you were MRD-negative and you went through a transplant, you didn't seem to get an advantage versus not. That was of maintenance with gilteritinib, I'll just sort of put that on there. But it's telling us more about who should get a transplant and who shouldn't and who should get maintenance after transplant and who shouldn't.  A really compelling study a year ago from I don't know what to call the British group now, we used to call them the MRC and then the NCRI. I'm not quite sure what to call their studies at the moment. But Dr. Jad Othman did a retrospective study a year ago that looked at patients who had NPM1 mutation, the most common mutation AML, and looked to see if you were MRD positive or MRD negative, what the impact of a transplant was. And if you're MRD negative there was not an advantage of a transplant, whereas if you're MRD positive there was. And when they stratified that by having a FLT3 mutation that cracked. If you had a FLT3 mutation at diagnosis but your NPM1 was negative in remission, it was hard to show an advantage of a transplant. So I think we're getting much more discriminating about who should or should not get a transplant by MRD testing for NPM1 and that includes the patients who have a concomitant FLT3 mutation. And we're really trying to learn more and more. Do we really need to be doing transplants in those who are MRD-negative? If you have adverse risk genetics and you're MRD-negative, I'll really need good data to tell me not to do a transplant, but I suspect bit by bit, we'll get that data. And we're looking to see if that's really the case there, too. So measurable residual disease testing is helping us discriminate, but there is still a core role of allogeneic transplant. And to reassure you, compared to, I think your allotransplant days were some time ago if I'm right. Dr. John Sweetenham: Yes. Dr. James Foran: Yeah. Well, compared to when you were doing transplants, they're better now and better for patients now. And we get people through graft versus host disease better, and we prevent it better. Dr. John Sweetenham: That's a great answer, James. Thanks for that. It really does help to put it in context, and I think it also leads us on very nicely into what's going to be my final question for you today and perhaps the trickiest, in a way. I think that everything you've told us today really emphasizes the fact that the complexity of AML treatment has increased, primarily because of an improved understanding of the molecular landscape of the disease. And it's a complicated area now. So do you have any thoughts on what type of clinical environment patients with AML should be evaluated and treated in in 2025? Dr. James Foran: Yeah, I want to give you a kind of a cautious answer to that because, you know, I'm a leukemia doctor. I work at a leukemia center and it's what we focus on. And we really pride ourselves on our outcomes and our diagnostics and our clinical trials and so on. I am very aware that the very best oncologists in America work in private practice and work in community practice or in networks, not necessarily at an academic site. And I also know they have a much harder job than I have. They have to know lung cancer, which is molecularly as complicated now as leukemia, and they have to know about breast cancer and things that I don't even know how to spell anymore. So it's not a question of competence or knowledge. It's a question of infrastructure. I'll also put a little caveat saying that I have been taught by Rich Stone at Dana-Farber, where I did a fellowship a long time ago, and believe Rich is right, that I see different patients than the community oncologists see with AML, they're seeing different people. But with that caveat, I think the first thing is you really want to make sure you've got access to excellence, specialized hematopathology, that you can get expedited cytogenetics and NGS testing results back. There was a new drug, approved just a few months ago, actually, for relapsed AML with a KMT2A rearrangement, revumenib. We didn't talk about the menin inhibitors. I'll mention them in just a second. That's a huge area of expansion and growth for us. But they're not found on NGS platforms. And normal cytogenetics might miss a KMT2A-rearrangement. And we're actually going back to FISH panels, believe it or not, on AML, to try to identify who has a KMT2A-rearrangement. And so you really want to make sure you can access the diagnostic platforms for that.  I think the National Referral Labs do an excellent job. Not always a really fast job, but an excellent job. At my institution, I get NGS results back within three days or four days. We just have an expedited platform. Not everybody has that. So that's the key, is you have to be able to make the diagnosis, trust the pathologist, get expedited results. And then it's the question of trying to access the targeted medications because a lot of them are not carried in hospital on formulary or take time to go through an insurance approval process. So that's its own little headache, getting venetoclax, getting gilteritinib, getting an IDH1 inhibitor in first line, if that's what you're going for. And so I think that requires some infrastructure. We have case managers and nurses who really expedite that and help us with it, but that's a lot of work. The other piece of the puzzle is that we're still with AML in the first month and maybe even the second month. We make everybody worse before we make them better. And you have to have really good blood bank support. I can give an outpatient platelet transfusion or red cell transfusion seven days a week. We're just built for that. That's harder to do if you're in a community hospital and you have to be collaborating with a local blood bank. And that's not always dead easy for somebody in practice. So with those caveats, I do find that my colleagues in community practice do a really good job making the diagnosis, starting people on therapy, asking for help. I think the real thing is to be able to have a regional leukemia center that you can collaborate with, connect with, text, call to make sure that you're finding the right patients who need the next level of diagnostics, clinical trial, transplant consults, to really get the best results.  There was some data at ASH a couple of years ago that looked at – the American Society of Hematology and ASCOs had similar reports – that looked at how do we do in academic centers versus community practice for keeping people on therapy. And on average, people were more likely to get six cycles of therapy instead of three cycles of therapy with azacitidine venetoclax at an academic center. Now, maybe it's different patients and maybe they had different cytogenetics and so on, but I think you have to be patient, I think you have to collaborate. But you can treat those patients in the community as long as you've got the infrastructure in place. And we've learned with virtual medicine, with Zoom and other platforms that we can deliver virtual care more effectively with the pandemic and beyond. So I think we're trying to offer virtual consults or virtual support for patients so they can stay in their home, stay in their community, stay with their oncologists, but still get access to excellent diagnostics and supportive care and transplant consults, and so on. I hope that's a reasonable answer to that question. It's a bit of a nuanced answer, which is, I think there's an important role of a leukemia center, and I think there's a really fundamental role of keeping somebody in the community they live in, and how we collaborate is the key to that. And we've spent a lot of time and effort working with the oncologists in our community to try to accomplish that.  John, I want to say two other things. I didn't mention in the molecular platforms that NPM1 mutations, we can now target those on clinical trials with menin inhibitors. We know that NPM1 signals through the Hoxa9/Meis1 pathway. We know that similar pathways are important in KMT2A rearrangements. We know that there are some other rare leukemias like those with NUP98 rearrangement. We can target those with menin inhibitors. The first menin inhibitor, revuminib, was approved by the FDA for KMT2A. We have others going to the FDA later this year for NPM1. There are now pivotal trials and advanced expanded phase 1/2 studies that are showing 30% response rates. And we're looking to see can we add those into the first-line therapy. So, we're finding more targets.  I'll say one last thing about molecular medicine. I know I'm a little off topic here, but I always told patients that getting AML was kind of like being struck by lightning. It's not something you did. Now, obviously, there are risk factors for AML, smoking or obesity or certain farm environments, or radioactive exposures and so on. But bit by bit, we're starting to learn about who's predisposed to AML genetically. We've identified really just in the last five or eight years that DDX41 mutations can be germline half the time. And you always think germline mutations are going to cause AML in a younger patient, but the median age is 60 to 70 just like other AMLs. They actually might do pretty well once they get AML. We've reported that in several papers. And so we're trying to understand who that has a RUNX1 mutation needs germline testing, who with a DDX41 needs germline testing. And we're trying to actually come up with a cleaner pathway for germline testing in patients to really understand predisposition, to help with donor selection, to help with family counseling. So I think those are other areas where a leukemia center can contribute for somebody in who's community practice to understand genomic or genetic complexity in these patients. And we're starting to develop the databases that support that. Dr. John Sweetenham: Yeah, great. Thanks, James. I loved your answer about the clinical environment too. And I know from a patient-centric perspective that I know that patients would certainly appreciate the fact that we're in a situation now where the folks taking care of them will make every effort to keep them close to home if they possibly can.  I want to thank you, James, for an incredible review of a very complex subject and I think you did a great job. I think we all will have learned a lot. And thanks again for being willing to share your insights with us today on the ASCO Daily News Podcast. Dr. James Foran: John, it's my pleasure. And as you know, I'll do anything for a latte, so no problem at all. Dr. John Sweetenham: Okay. I owe you one, so thank you for that.  And thank you to our listeners for your time today. You'll find links to the studies we've discussed today in the transcript of this episode. And finally, if you value the insights that you hear on the ASCO Daily News Podcast, please take a moment to rate, review and subscribe wherever you get your podcasts. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity or therapy should not be construed as an ASCO endorsement. Find out more about today's speakers:  Dr. John Sweetenham  Dr. James Foran Follow ASCO on social media: @ASCO on Twitter ASCO on Bluesky ASCO on Facebook  ASCO on LinkedIn  Disclosures:    Dr. John Sweetenham:    No relationships to disclose Dr. James Foran: Stock and Other Ownership Interests: Aurinia Pharmaceuticals Consulting or Advisory Role: Peerview, CTI BioPharma Corp, Remix Therapeutics, Cardinal Health, Medscape, Syndax, Autolus Therapeutics Research Funding (Inst.): Chordia Therapeutics, Abbvie, Actinium Pharmaceuticals, Kura Oncology, Sellas Life Sciences, Novartis, Roivant, Celgene/Bristol-Myers Squibb, Astellas Pharma, SERVIER Travel, Accommodations, Expenses: Peerview

In this week's episode we'll find out about longer term results from a pivotal trial of mosunetuzumab in relapsed/refractory follicular lymphoma, potential use of CD70 CAR T-cells that secrete an anti-CD33/anti-CD3 bispecific antibody as a therapy for acute myeloid leukemia, and how ferroptosis regulates hemolysis in stored red blood cells.Featured Articles:Long-term 3-year follow-up of mosunetuzumab in relapsed or refractory follicular lymphoma after ≥2 prior therapiesCD70 CAR T cells secreting an anti-CD33/anti-CD3 dual-targeting antibody overcome antigen heterogeneity in AMLFerroptosis regulates hemolysis in stored murine and human red blood cells

In this week's episode we'll learn more about a phase 2 trial of first-line zanubrutinib, obinutuzumab, and venetoclax in TP53-mutated mantle cell lymphoma; early development of hyperdiploidy in multiple myeloma; and a phase 1 trial of the asparaginase pegcrisantaspase plus venetoclax in relapsed/refractory acute myeloid leukemia.Featured Articles:Zanubrutinib, obinutuzumab, and venetoclax for first-line treatment of mantle cell lymphoma with a TP53 mutationDevelopment of hyperdiploidy starts at an early age and takes a decade to completeA phase 1 study of the amino acid modulator pegcrisantaspase and venetoclax for relapsed or refractory acute myeloid leukemia

Send Me a textIn today's episode, I talk about the start of the nonprofit Penelope's dad and I decided to start in our community after our daughter's diagnosis of Acute Myeloid Leukemia.In this episode, we cover:* The Story behind how the nonprofit organization started* The importance of your community and meeting them where they are at* Connect with us:* Instagram: @penelopesupportsquad* Website: www.peneloperae.orgIf you loved this episode, be sure to hit subscribe/follow!

Marlies Alves shares her journey from being a registered nurse to becoming a cancer patient, highlighting the importance of nutrition in overall health. She candidly discusses her experiences with acute myeloid leukemia, conventional cancer treatment, and how she found healing through holistic practices.• Growing up in Rhode Island after losing her father• Becoming a nurse and her early experiences in healthcare• Mother's colon cancer diagnosis sparks a passion for nutrition• Navigating her own cancer diagnosis and treatment• Advocating for nutrition in the hospital setting• Transitioning from conventional treatments to holistic health coaching• Launching Healing Strong group to support others in their journeys• Reinforcing the importance of taking charge of one's health• Finding purpose in sharing her story with othersContact Marlice:magoosrn@gmail.comRI Group LeaderHealingStrong's mission is to educate, equip and empower our group leaders and group participants through their journey with cancer or other chronic illnesses, and know there is HOPE. We bring this hope through educational materials, webinars, guest speakers, conferences, community small group support and more.Please consider supporting our mission by becoming a part of our Membership Program, as a monthly donor.When you do, you will receive additional resources such as: webinars, access to ALL our past and most recent conference videos, downloadables and more, as a bonus.To learn more, head to the HealingStrong Membership Program link below: Membership Program

Featuring perspectives from Dr Alexander Perl, Dr Eytan M Stein, Dr Richard M Stone, Dr Eunice S Wang and Prof Andrew H Wei, moderated by Dr Stein, including the following topics: Introduction (0:00) Treatment for Older Patients with Acute Myeloid Leukemia (AML) — Prof Wei (2:48) Selection of Initial Therapy for Younger Patients with AML without a Targetable Mutation, Including Those with Secondary AML — Dr Stone (26:52) Role of FLT3 Inhibitors in AML Management — Dr Perl (49:41) Incorporation of IDH Inhibitors into the Care of Patients with AML — Dr Stein (1:13:57) Potential Role of Menin Inhibitors and Other Novel Agents in the Treatment of AML — Dr Wang (1:35:50) CME information and select publications

Dr Alexander Perl from Abramson Cancer Center in Philadelphia, Pennsylvania, Dr Richard M Stone from Dana-Farber Cancer Institute in Boston, Massachusetts, Dr Eunice S Wang from Roswell Park Comprehensive Cancer Center in Buffalo, New York, Prof Andrew H Wei from Walter and Eliza Hall Institute of Medical Research in Melbourne, Australia, and moderator Dr Eytan M Stein from Memorial Sloan Kettering Cancer Center in New York, New York, discuss updated data from ASH 2024 influencing the current and future treatment paradigm for treatment-naïve and relapsed/refractory acute myeloid leukemia.

Dr Alexander Perl from Abramson Cancer Center in Philadelphia, Pennsylvania, Dr Richard M Stone from Dana-Farber Cancer Institute in Boston, Massachusetts, Dr Eunice S Wang from Roswell Park Comprehensive Cancer Center in Buffalo, New York, Prof Andrew H Wei from Walter and Eliza Hall Institute of Medical Research in Melbourne, Australia, and moderator Dr Eytan M Stein from Memorial Sloan Kettering Cancer Center in New York, New York, discuss updated data from ASH 2024 influencing the current and future treatment paradigm for treatment-naïve and relapsed/refractory acute myeloid leukemia. Produced by Research To Practice. CME information and select publications here (https://www.researchtopractice.com/ASHAML24).

This podcast Clinical Clip features a leading expert highlighting the latest advances in Acute Myeloid Leukemia(AML) treatments presented at the 66th ASH Annual Meeting and Exposition from December 7-10, 2024, in San Diego, CA.Launch Date: December 16, 2024Release Date: December 16, 2024Expiration Date: November 30, 2025FACULTYNaval Daver, MDDirector, Leukemia Research Alliance Program,Professor of MedicineDepartment of LeukemiaMD Anderson Cancer CenterThis podcast provides accredited continuing education credits.  To receive your credit, please read the accreditation information provided at this link prior to listening to this podcast.

In this episode of the Bench to Bedside Podcast, Dr. Roy Jensen, vice chancellor and director of The University of Kansas Cancer Center, discusses exciting advancements in the treatment of acute myeloid leukemia (AML) with Dr. Tara Lin, director of the adult leukemia program at KU Cancer Center and site principal investigator for myeloMATCH (Myeloid Malignancies Molecular Analysis for Therapy Choice), a precision-medicine initiative sponsored by the National Cancer Institute (NCI). MyeloMATCH is an “umbrella trial,” a group of clinical substudies for people with acute myeloid leukemia or myelodysplastic syndrome. In this conversation Dr. Lin explains the challenges of AML, as well as the innovative aspects of the myeloMATCH trial, such as rapid diagnostic testing and specialized clinical trial options based on genetic and molecular features. Do you have questions about cancer? Call our Bench to Bedside Hotline at (913) 588-3880 or email us at benchtobedside@kumc.edu, and your comment or question may be shared on an upcoming episode! If you appreciated this episode, please share, rate, subscribe and leave a review. To ensure you get our latest updates, For the latest updates, follow us on the social media channel of your choice by searching for KU Cancer Center. Links from this Episode: Learn more about the myeloMATCH trial View the myleoMATCH trial on the NCI's clinical trials database Learn more about AML Read about clinical trials at KU Cancer Center Learn more about Dr. Tara Lin

How appropriate are cholesterol-lowering guidelines? Are Americans really ready for bans on colorful synthetic food dyes? New powerful drugs promise to slash LDL cholesterol—but are they overused? How to stay fit when arthritis limits exercise; The genetics of acute myeloid leukemia; Cattle feed Bovaer promises to curb methane emissions—but critics claim it's toxic; Carrageenan may prompt insulin resistance, systemic inflammation; Should you really toss that black plastic spatula?

In this episode of #MovingMedicineForward – The Podcast, CTI experts Chad Jones & Eric Clayton discuss challenges in clinical research surrounding Acute Myeloid Leukemia (AML) & Multiple Myeloma (MM). They explore the complexities of designing & conducting clinical trials, the importance of site selection, & how CTI's expertise enhances trial outcomes. Additionally, they touch on key advancements to watch at the 66th American Society of Hematology Annual Meeting. During the episode, Eric explains how, “These are some of the first times that these therapies are being tried in human participants, & that innovative experimentation is what makes this work so exciting.” 0:22 Challenges in clinical research for Acute Myeloid Leukemia (AML) and Multiple Myeloma (MM), with insights from CTI experts Chad Jones, Sr. Director of Project Management and Oncology Strategy Lead, and Eric Clayton, Clinical Project Manager III.  0:51 Overview of AML and MM, and why these diseases are particularly difficult to treat.  1:32 Key challenges in designing and conducting clinical trials for AML and MM.  3:19 How site selection and management impact trial success, and challenges Contract Research Organizations (CROs) face when recruiting qualified sites.  5:14 How CTI's expertise supports sponsors and improves trial outcomes.  6:38 The importance of maintaining proper chain of custody.  9:53 Key treatments and advancements in hematology to watch at the 66th ASH Annual Meeting.  10:33 Visit CTI at booth #454 at ASH.  10:41 Regulatory considerations for treatments and how CTI navigates this process for patients.  12:31 Collaboration between CROs, pharmaceutical companies, and academic institutions to accelerate research.  13:12 Unmet needs in AML and MM research and how the industry can address them.  14:16 Challenges in improving patient outcomes for MM and AML.  16:22 How CTI mitigates patient retention during clinical trials.  18:33 Strategies for recruiting critically ill MM and AML patients.  21:41 CTI is recruiting a Sr. Medical Director in Hematology/Oncology. Apply now: Senior Medical Director - Hematology/Oncology - Level Dependent Upon Experience | Join The CTI Team  

Tommy Stackhouse was diagnosed with Acute Myeloid Leukemia just two weeks before his 16th birthday in May of 2019. Tommy graduated from High School and during his senior year he was voted Homecoming King. After two Stem Cell Transplants and while Tommy was studying at a Community College, Tommy's health became a serious problem and he passed away from this most difficult form of Blood Cancer on May 26th of 2022. 

In this week's episode we'll learn more about a new risk classification scheme for use in patients with acute myeloid leukemia who are ineligible for intensive therapy, efficacy and safety of daratumumab plus chemotherapy in pediatric patients with acute lymphoblastic leukemia or lymphoblastic lymphoma, and a blood bank-compatible method for creating genetically engineered platelets with a wide range of potential uses.Featured Articles:Genetic Risk Stratification and Outcomes Among Treatment-Naive Patients with AML Treated With Venetoclax and Azacitidine Daratumumab in Pediatric Relapsed/Refractory Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma: DELPHINUS Study Genetic Engineering of Transfusable Platelets with mRNA-Lipid Nanoparticles is Compatible with Blood Banking Practices  

Immunotherapy and targeted therapies have transformed the way patients are treated and allow more patients than ever before to survive stage IV diagnoses. Other key advancements in oncology being prioritized in Puerto Rico today include early detection and prevention efforts. However, a lack of education, access, and health insurance coverage often prevents community members from timely cancer screenings. The same factors contribute to a lack of diversity in clinical trials, as noted by Dr. Marcia Cruz-Correa. Both these important issues require a community-based approach, through building advisory groups, working with local oncologists, and reaching community members where they are in a way they understand. Guest:  Marcia Cruz-Correa, MD, PhD, AGAF, FASGEExecutive DirectorCentro Comprensivo de Cáncer de la Universidad de PuertoSan Juan, Puerto Rico Quote:  “Less than 5% of patients in the US participate in clinical trials...and less than 5% of that [group] is diverse. That's a huge disadvantage...If you don't include the patients who will eventually be taking the drugs developed by pharmaceutical companies, how do you know it will work for them?” Read more global perspectives from the international panelists who spoke at the October ACCC 41st National Oncology Conference in this ACCCBuzz blog. Additional Resources:  Bridging the Gap: Early Detection of Cancer for the Medically Underserved – Oncology Issues Effective Patient-Provider Communication for Colorectal Cancer Screening Multi-Cancer Early Detection: Legislative Landscape— [PODCAST] EP 99 Examining Clinical Research for Patients with Acute Myeloid Leukemia 2023 NMQF Summit: Improving Diversity in Cancer Clinical Trials

In this episode of the Oncology Brothers podcast, hosts Drs. Rahul and Rohit Gosain are joined by Dr. Mikkael Sekeres, Professor of Medicine and Chief of the Division of Hematology at the University of Miami. Together, they explore the complex landscape of acute myeloid leukemia (AML), discussing the latest advancements in diagnosis, treatment options, and risk stratification. Key topics included: •⁠ ⁠The importance of molecular testing in AML diagnosis and treatment planning •⁠ ⁠The role of intensive induction chemotherapy and the classic 7+3 regimen •⁠ ⁠New oral therapies, including FLT3 inhibitors and hypomethylating agents combined with venetoclax •⁠ ⁠Strategies for managing elderly or frail patients who are ineligible for intensive chemotherapy •⁠ ⁠The significance of measurable residual disease (MRD) in treatment decisions and transplant eligibility •⁠ ⁠Insights into managing side effects and complications associated with AML treatments Join us for an informative discussion that sheds light on the evolving treatment landscape of AML and the importance of personalized care in oncology. Don't forget to check out our other episodes on hematological malignancies, and we look forward to seeing you at ASH 2024!   Subscribe to our channel for more insights and updates in the world of oncology! Website: http://www.oncbrothers.com/ X/Twitter: https://twitter.com/oncbrothers Contact us at info@oncbrothers.com

Matt Waning's cancer journey began in 2021, at the age of 34, when he wasdiagnosed with testicular cancer. The aggressive nature of his illness led to surgery that removed a tumor the size of a watermelon, along with his left testicle and kidney, as the tumor had reached his aorta. Following surgery, he underwent two months of preventive chemotherapy known as VIP treatment and celebrated being in remission by August 2021. However, the VIP treatment came with a rare side effect—a potential risk of developing acute myeloid leukemia (AML). Unfortunately, in January 2023, Matt was diagnosed with AML as a result of the chemotherapy he had previously received. Matt is an avid Boston sports fan, with a particular passion for the Bruins. Musicis another love of his, offering solace and joy throughout his journey. As the oldest of three siblings, he shares a special bond with his family, including his dog Mogley, named after the main character from "The Jungle Book." Dr. Stone is currently the Director of the Adult Acute Leukemia Program atDana-Farber Cancer Institute, serves on the Medical Oncology Board of the American Board of Internal Medicine, and is vice chair of the Leukemia Core Committee for the national cooperative trials group Cancer and Leukemia Group B. As the Senior Leukemia Protocol Research Nurse Practitioner at Dana-FarberCancer Institute, Ilene Galinsky practices autonomously and in collaboration withphysicians and other members of the multidisciplinary team in the diagnosis, treatment, and management of patients with acute and chronic myelogenous leukemia (CML), myelodysplastic syndrome (MDS), myelofibrosis, and other bone marrow failure diseases.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/YGR865. CME/MOC/NCPD/AAPA/IPCE credit will be available until July 1, 2025.Unleashing the Innovation Era in AML: Practice Principles and Precision Medicine With Innovative Therapeutics In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and HealthTree Foundation for Acute Myeloid Leukemia. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through independent educational grants from AbbVie, Astellas, Bristol Myers Squibb, Daiichi Sankyo, Inc., Kura Oncology, Inc., and Rigel Pharmaceuticals, Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/YGR865. CME/MOC/NCPD/AAPA/IPCE credit will be available until July 1, 2025.Unleashing the Innovation Era in AML: Practice Principles and Precision Medicine With Innovative Therapeutics In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and HealthTree Foundation for Acute Myeloid Leukemia. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through independent educational grants from AbbVie, Astellas, Bristol Myers Squibb, Daiichi Sankyo, Inc., Kura Oncology, Inc., and Rigel Pharmaceuticals, Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/YGR865. CME/MOC/NCPD/AAPA/IPCE credit will be available until July 1, 2025.Unleashing the Innovation Era in AML: Practice Principles and Precision Medicine With Innovative Therapeutics In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and HealthTree Foundation for Acute Myeloid Leukemia. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through independent educational grants from AbbVie, Astellas, Bristol Myers Squibb, Daiichi Sankyo, Inc., Kura Oncology, Inc., and Rigel Pharmaceuticals, Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/YGR865. CME/MOC/NCPD/AAPA/IPCE credit will be available until July 1, 2025.Unleashing the Innovation Era in AML: Practice Principles and Precision Medicine With Innovative Therapeutics In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and HealthTree Foundation for Acute Myeloid Leukemia. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through independent educational grants from AbbVie, Astellas, Bristol Myers Squibb, Daiichi Sankyo, Inc., Kura Oncology, Inc., and Rigel Pharmaceuticals, Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/YGR865. CME/MOC/NCPD/AAPA/IPCE credit will be available until July 1, 2025.Unleashing the Innovation Era in AML: Practice Principles and Precision Medicine With Innovative Therapeutics In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and HealthTree Foundation for Acute Myeloid Leukemia. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through independent educational grants from AbbVie, Astellas, Bristol Myers Squibb, Daiichi Sankyo, Inc., Kura Oncology, Inc., and Rigel Pharmaceuticals, Inc.Disclosure information is available at the beginning of the video presentation.

Welcome back! After 2 months off, I'm so thrilled to be releasing another episode! I'm deeply sad that Austin's story needs to be told at all… or rather that his life took the turn it did. This week's episode explains how my 2nd born, Austin, was diagnosed with Acute Myeloid Leukemia on May 2, 2024 and what's been happening since then. Two graduations, a wedding, a canceled race, an impromptu 20k…and lots more. As always, thank you so much for listening and please reach out to funoftherunpodcast@gmail.com or DM me on Instagram @waddellrunninglady with feedback or questions. Thank you!

Witness Wednesday #118 More PopWe (Healing)Today's witnesses are from Matthew West's website called popwe.org. If you don't know who Matthew West is, he is a singer, songwriter, and storyteller. This website is for the non-profit that he has with his father, a pastor. Matthew and his father encourage people to share their stories. They have various categories of stories. Today I chose four testimonies from the Healing Category. I know so many people who are praying for a miraculous healing right now. Oftentimes, we can hear our own story in someone else's story. When we hear others tell their story it helps us to see we are not alone. When we see that others were healed it gives us hope that if God could heal them then He can heal us too! I pray when you hear these testimonies, you get the faith and hope to believe that you and your loved ones could be healed too!Savannah: This story isn't about me, but my brother. It was August of 2020 when he was admitted to the hospital with COVID. We were told right from the beginning that it didn't look good. What followed was a long battle for his life. He needed a form of life-support that had extremely limited availability. He needed so much blood. His wife and children couldn't come to see him. At one point, his heart stopped for 8.5 minutes. The only thing we could do was pray. It was nearly spring when he finally went home to his family. He's alive, and nobody can deny that a miracle has taken place. We prayed without ceasing, and God has answered our prayers.Deborah:  I grew up in an extremely dysfunctional family. I wasn't allowed to listen to music, watch animated movies, or basically like any food or activities that my father did not like. I was often told that if I asked for help I was bothering people, that I was stupid, and that a “good guy” would never like me so I would have to settle for a “bad one.”I've gone to counseling for awhile and with God's help, I have begun to heal in many ways. However, there was one thing that I had not been able to do and that was to let myself cry. Crying when I was young was dangerous and was always met with the words, “Jesus doesn't love you if you cry.”  Intellectually, I knew this wasn't true and that it was okay to cry but it didn't feel safe. I had taught myself not to cry for so long that I wasn't sure if I could. It was as if the tears were broken.Last night, I was at the concert in Gadsden, AL, and I began to feel emotional as I listened to dad jokes and as Matthew West talked about being a girl dad. Memories of my childhood and the things I was told began to pop into my mind. Still I did not cry. I sat on the front row wondering if anyone could tell that I was fighting tears. Then something changed. John 3:16 was read and everyone was told to insert their own name. As I was fighting tears, I was saying the words “God loves me.”Suddenly I didn't just know that intellectually it is okay to cry, I knew it in my heart. God loves me even when I cry. During the next song, I felt something on my face and I reached up and there was a tear. For the first time in probably thirty years I was letting myself cry and I felt safe while doing it. I am not who my family told me that I am. I am a child of God. I am safe in his arms and loved when I'm happy and smiling and even when I'm sad and crying.Kathleen:  Not the healing I wanted…thank goodness, God knew better what I needed. In late 2016 and 2017 I was suffering from a crippling case of Bi-Polar disorder.My doctor prescribed me several different antidepressants, however, all of them left me with feelings of deep depression and high anxiety. By mid-January, my husband and I agreed to discontinue all medication and look for a more holistic treatment. I was on antidepressants for a total of SIX WEEKS when I began the withdrawal process. By mid-April, I was finally feeling free from the effects of the medication and 30 pounds lighter. My anxiety was greatly reduced and my depression was almost a non-issue. Then a week later, after a nice hot soak in the tub, I started experiencing weird “pins and needles” in my left leg, from the knee to my ankle. I tried rubbing, slapping it, walking around the house-nothing worked and I ended up going to bed hours later with the buzz still going strong.Within a month, the buzz had moved to my entire left side, from the neck down. Another month down the road and it was on my right side also. Trips to my doctor, the neurologist, MRI, CAT scan, EEG, EMG proved fruitless- except now I had a name. Spontaneous Paresthesia. You know when your foot falls asleep and in the “waking up” process you get the feeling of pins and needles? By the middle of June, paresthesia was affecting my entire body. One day, while working around the house with my husband, I became completely unglued when I started feeling my stomach, intestines, internal organs, all buzzing. Everywhere I have nerve endings I felt buzzing. By July, 2017, I felt like I had bugs crawling in my ears, fleas stuck up my nose, lice crawling around my scalp, and the force of buzzing was starting to hurt. Every night before going to bed I only had one prayer, “Jesus, please take me home. I don't want to wake up in this bed again.”Soon, I was no longer able to sleep at night because of the violent buzzing. I listened exclusively to Christian Radio (KLOVE) and one day I heard a song that spoke to the heart of my fear. Toby Mac's “MOVE” said it better than I was able to articulate: “I know your heart's been broke again, I know your prayers ain't been answered yet. I know you feel like you've got nothing left. But just lift your head… It ain't over yet.”Within a month I would find another neurologist who still didn't have a clue as to what the cause of my paresthesia was, but he did have medication that might be helpful. –IT WAS! Within a few days I was sleeping again. I could sit down again. I could think clearly again. Paresthesia ceased to be the center of my universe. Do I still have paresthesia? YES. I stopped touching my face long before covid because I hate the numb/tingling feeling I get every time I touch my nose, ears, chin, eyes. Within a year, my prayer each night changed from “Jesus, take me home”  to “Thank you Lord for paresthesia.”My relationship with my God was good, now it's deep. I am 67 years old and I know…”it ain't over yet.”  I just got back from my second mission trip to Amman, Jordan where I had the privilege of teaching Iraqi refugee women sewing skills. I didn't get the healing I wanted- what I got was so much better. I haven't had another bi-polar incident since January 2017. By experiencing paresthesia, God was giving me a crash course to knowing and trusting Him.Devon: I'm a living, breathing, walking miracle. My friends call me Lazarus!In 2014, I was a single mom to a 6 year-old son. I went to get some blood work done on a Friday afternoon, because I was feeling run down. Monday morning, I got a call saying I needed to get to the nearest emergency room, that my blood levels were critical.I ended up having Acute Myeloid Leukemia, the worst possible case. I was immediately hospitalized and given chemo. After my 2nd round of chemo, all my organs shut down, I had congestive heart failure, and slipped into a coma. My hands and feet turned black in the dying process. The doctors told my parents I had days, possibly hours to live with zero chance of survival. My little boy was brought to my bedside to say goodbye to me. My friends and family surrounded my hospital bed and prayed for a miracle.On the 30th day, I woke up. All my organs went back to normal, and I was able to get a stem cell transplant. This was seven years ago this week. Thank you, Jesus, for healing me.Thank you all for sharing your stories with us. We must share our healing stories because it gives others the hope that they will be healed. It is also important to share healing stories because it ensures that God gets all the glory!! Thank you for being brave enough to share your story so others can see what is possible. www.findingtruenorthcoaching.comCLICK HERE TO DONATECLICK HERE to sign up for Mentoring CLICK HERE to sign up for Daily "Word from the Lord" emailsCLICK HERE to sign up for free audio training about inviting Jesus into your daily lifeCLICK HERE to buy my book Total Trust in God's Safe Embrace

In this episode, listen to Professor Eunice S. Wang, MD, share her clinical insights and takeaways on new data for acute myeloid leukemia (AML) presented at the 2024 ASCO annual meeting and the EHA 2024 Congress including:Data from the prospective, single-center phase Ib/II study of FLAG-IDA plus venetoclax in newly diagnosed or relapsed/refractory AML Phase I/II study of oral decitabine/cedazuridine with venetoclax and gilteritinib in patients with newly diagnosed and relapsed/refractory FLT3-mutant AMLA retrospective comparison of abbreviated course 7+7 vs standard HMA plus venetoclax doublet in older/unfit patients with newly diagnosed AML Multisite randomized trial of a collaborative palliative and oncology care model for patients with AML and myelodysplastic syndromes (MDS) receiving nonintensive therapyFinal 5-year results from the phase II pivotal cohort of olutasidenib for IDH1-mutated AML Post hoc analyses of outcomes in patients with AML and MDS-related changes who received oral azacitidine maintenance therapy in the phase III QUAZAR AML-001 studyFirst-in-human phase I/II of the menin-MLL inhibitor DSP-5336 in patients with R/R acute leukemia: updated results from the dose escalation phase A phase Ib study of the menin-KMT2A inhibitor bleximenib in combination with venetoclax and azacitidine in R/R AML with alterations in KMT2A or NPM1 Program faculty:Eunice S. Wang, MDChief, Leukemia and Benign Hematology ServiceProfessor of OncologyRoswell Park Comprehensive Cancer CenterBuffalo, New YorkCourtney DiNardo, MD, MSCEProfessor of MedicineDepartment of LeukemiaMD Anderson Cancer CenterHouston, TexasResources:To download the slides associated with this podcast discussion, please visit the program page:https://bit.ly/4bvJGij

Today's episode is an update on AML (acute myeloid leukemia). In Part 2 we discuss the treatment options for first-line, as well as relapsed/refractory disease. We are so honored to have Dr. Catherine Lai here with us who is Associate Professor and Physician Leader of the Leukemia Clinical Research Unit at UPenn.

Today's episode is an update on AML (acute myeloid leukemia). In Part 1 we discuss the usual presentation, diagnostic work-up, and updates on the classification of AMLs. We are so honored to have Dr. Catherine Lai here with us who is Associate Professor and Physician Leader of the Leukemia Clinical Research Unit at UPenn.

Melissa Rodger's then 9 year old daughter Chloe  had a lingering cold in July of 2022 and was told by a doctor that her cold was just a product of "back to back" viruses. Not too long after that Chloe was dehydrated and this time she was sent to a hospital emergency room where she was quickly diagnosed with Acute Myeloid Leukemia. Chloe had to undergo 2 Bone Marrow transplants with first, Melissa, and then her father Luke being her donors. Today Chloe is back in school, doing very well, and hopes to graduate from 6th grade when the academic year ends in December. Melissa will also talk about her own hard fought battles with Anxiety on today's podcast. 

Upon diagnosing acute myeloid leukemia (AML), the initial step involves assessing a patient's eligibility for intensive chemotherapy. The standard treatment protocol for newly diagnosed AML encompasses intensive chemotherapy to achieve complete remission, followed by post-remission therapy, which may include additional chemotherapy and/or stem cell transplantation. Complete response rates to this approach range from 60% to 85% in adults aged 60 or younger. While this approach has proven effective, the risk of relapse within three years of diagnosis remains a significant concern. Numerous factors contribute to the likelihood of relapse, including short duration of remission, genetic derangements, prior allogeneic transplantation, advanced age, and concomitant comorbidities. These negative prognostic factors underscore the need for continuous exploration of novel therapeutic agents, as relapse remains a formidable barrier to treatment success. In a new study, researchers Simonetta I. Gaumond, Rama Abdin, Joel Costoya, Andrew V. Schally (awarded the Nobel Prize in Physiology or Medicine in 1977), and Joaquin J. Jimenez from the University of Miami, Florida Atlantic University and Veterans Affairs Medical Center, Miami, investigated newly emerging therapies targeting drug resistance in AML. On April 8, 2024, their new research paper was published in Oncotarget's Volume 15, entitled, “Exploring the role of GHRH antagonist MIA-602 in overcoming Doxorubicin-resistance in acute myeloid leukemia.” Full blog - https://www.oncotarget.org/2024/05/23/combating-doxorubicin-resistant-acute-myeloid-leukemia/ Paper DOI - https://doi.org/10.18632/oncotarget.28579 Correspondence to - Simonetta I. Gaumond - sxg1204@miami.edu Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.28579 Subscribe for free publication alerts from Oncotarget - https://www.oncotarget.com/subscribe/ Keywords - cancer, leukemia, AML, resistance, growth hormone-releasing hormone, MIA-602 About Oncotarget Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science. Oncotarget is indexed and archived by PubMed/Medline, PubMed Central, Scopus, EMBASE, META (Chan Zuckerberg Initiative) (2018-2022), and Dimensions (Digital Science). To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us: Facebook - https://www.facebook.com/Oncotarget/ X - https://twitter.com/oncotarget Instagram - https://www.instagram.com/oncotargetjrnl/ YouTube - https://www.youtube.com/@OncotargetJournal LinkedIn - https://www.linkedin.com/company/oncotarget Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget/ Spotify - https://open.spotify.com/show/0gRwT6BqYWJzxzmjPJwtVh MEDIA@IMPACTJOURNALS.COM

The joy of the birth of Savannah Hansen on July 6th of 2023 was muted as there were bruises all over her tiny body as she was born. These bruises signified Acute Myeloid Leukemia. Savannah's mom Sarah will talk about her ordeal which ended up with Savannah being transferred from her local hospital in Las Vegas to Children's Hospital of Los Angeles where she completed her treatment on January 29th of 2024. Savannah is doing as well as possible health wise.  

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Acute Myeloid Leukemia | Faculty Presentation 2: Available and Emerging Nontargeted Therapies for AML — Naval Daver, MD CME information and select publications

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Acute Myeloid Leukemia | Faculty Presentation 1: Current and Emerging Role of Biomarker-Directed Therapeutic Approaches for Patients with Acute Myeloid Leukemia (AML) — Courtney D DiNardo, MD, MSCE CME information and select publications

Featuring perspectives from Dr Naval Daver and Dr Courtney D DiNardo, including the following topics: Introduction (0:00) Available and Emerging Nontargeted Therapies for Acute Myeloid Leukemia (AML) —Dr Daver (6:47) Current and Emerging Role of Biomarker-Directed Therapeutic Approaches for Patients with AML —Dr DiNardo (32:58) CME information and select publications

Drs Naval Daver and Courtney D DiNardo, both from The University of Texas MD Anderson Cancer Center in Houston, summarize the clinical progress in diagnosing and treating acute myeloid leukemia over the past year, as well as practical considerations for patients with the disease.

Drs Naval Daver and Courtney D DiNardo, both from The University of Texas MD Anderson Cancer Center in Houston, summarize the clinical progress in diagnosing and treating acute myeloid leukemia over the past year, as well as practical considerations for patients with the disease, moderated by Dr Neil Love. Produced by Research To Practice. CME information and select publications here (https://www.researchtopractice.com/YiR2023/AML).

Join Drs. Timothy Cripe and Marco Davila as they discuss a recent article published in the December issue of Molecular Therapy Oncology by Dr. Davila and colleagues titled, Bispecific CD33/CD123 targeted chimeric antigen receptor T cells for the treatment of acute myeloid leukemia. Dr. Timothy Cripe: Editor-in-Chief of Molecular Therapy Oncology and Professor and Chief of Hematology/Oncology/BMT at Nationwide Children's Hospital Dr. Marco Davila, Rustum Family Endowed Chair in Translational Research, Senior Vice President and Associate Director for Translational Research, Department of Medicine and Immunology, Roswell Park Comprehensive Cancer Center Host: Dr. Rory Bricker-Anthony, Scientific Editor of the Molecular Therapy Family of Journals ASGCT members save $385 on registration rates for the ASGCT Annual Meeting whether you're attending in person or virtually! Bundle both ASGCT membership and Annual Meeting attendance and save big on attending the premier event in the field. Register today at annualmeeting.asgct.org. 'Electric Dreams' by Scott Buckley - released under CC-BY 4.0.www.scottbuckley.com.auShow your support for ASGCT!: https://asgct.org/membership/donateSee omnystudio.com/listener for privacy information.

EP. 91 Navigating Diverse Hospice Experiences: A Family's Journey This episode of 'Hospice Explained' features host Marie Betcher RN in conversation with guest Lee Ann Pepper, who shares her contrasting experiences with hospice care for her parents. Lee Ann recounts her mother's journey with Acute Myeloid Leukemia and her peaceful transition into hospice care at home, emphasizing the personalized and compassionate approach of hospice services that fostered a comforting end-of-life experience. In contrast, she describes her father's struggle with Parkinson's and the challenges posed by his hospice care during the COVID-19 pandemic, including restrictions on visitations and difficulties in addressing his anxiety and discomfort. The discussion highlights the importance of understanding each patient's unique needs, the impact of external factors such as the pandemic on hospice care, and the potential areas for improvement in communicating and addressing patients' and families' needs. 00:00 Introduction to Hospice Explained 00:32 Guest Introduction: Lee Ann Pepper's Unique Hospice Experiences 01:26 Lee Ann's Mother's Hospice Journey: A Story of Compassion and Closure 05:18 The Hospice Experience: Comfort Over Cure 09:59 Lee Ann's Father's Hospice Journey: Challenges and Differences 10:30 Navigating Hospice Care During COVID-19 25:12 Reflections on Hospice Care and Its Impact 25:52 Closing Thoughts and Encouragement to Volunteer     Lee Ann's Contact:  Leeann.classreunion@gmail.com  Instagram leeann_classreunion TikTok leeann_classreunion https://www.youtube.com/watch?v=PvlLTttbs3A   Marie's Contact:  Buying from the Death Deck affiliate will help support this Podcast. In addition you can donate to help support at the Buy me a Coffee link-Please and Thank YOU!! 206-705-3080 Marie@HospiceExplained.com www.HospiceExplained.com https://thedeathdeck.goaffpro.com/ https://www.buymeacoffee.com/Hospice

While social determinants of health can impact access to care and treatment options for many patients with cancer, when combined with the complexities of acute myeloid leukemia, these factors become critical to treatment outcomes and quality of life for patients. In this episode, CANCER BUZZ speaks with Linda Hayward, patient financial advocate at the University of Maryland, Kaufman Cancer Center at Upper Chesapeake Health, about the challenges of treatment and strategies to address disparities in access and care for patients with acute myeloid leukemia. “When patients are financially underserved [this] plays a major factor in a patient getting treatment…if we [financial advocates] were not here to help our patients, many would forgo treatments.” –Linda Hayward, Patient Financial Advocate “Patient financial advocates can help patients navigate different resources……if we [financial advocates] were not here to help our patients, many would forgo treatments.” –Linda Hayward, Patient Financial Advocate   Guest:             Linda Hayward Patient Financial Advocate University of Maryland, Kaufman Cancer Center at Upper Chesapeake Health Bel Air, Maryland   This episode was developed as a part of the ACCC education program Addressing Disparities in Access to Care for Acute Myeloid Leukemia, designed to explores the current challenges in care coordination and therapy options for patients with acute myeloid leukemia and highlights strategies and best practices to improve outcomes for these patients. This episode was made possible with support by AbbVie.   Additional Reading/Sources ·       Strategies to Addressing Disparities in Patients with AML [Video Podcast] ·       Improving Care Delivery for Transplant-Ineligible Patients with AML ·       ACCC Financial Advocacy Service Guidelines ·       AML Care Coordination in the Community Setting [Video Podcast] ·       Critical Conversation Strategies for Patients with AML [Video Podcast] ·       Shared Decision-making in Acute Myeloid Leukemia ·       Achieving and Maintaining Better Outcomes for Patients with AML ·       Talking about Acute Myeloid Leukemia (Cancer Support Community) ·       Shared Decision-making: Practical Implementation for the Oncology Team (ACCC)

After little Charlie Stevens was taken to his doctor after he developed a lesion in his right eye, it became apparent that he had too many white blood cells, but an X Ray and ultrasound showed him to be healthy in the early days of 2020. Just six weeks later Charlie was diagnosed with Acute Myeloid Leukemia. A very aggressive treatment protocol led to his remission that year but just before Christmas Charlie relapsed and he passed away on January 27th, of 2021, just 2 days after his 3rd birthday. Charlie's mother Kelly will talk about her beloved son, and how she has become an activist in her native home of Adelaide Australia to help other AML and Pediatric Cancer patients and their families. 

Maintenance therapy for patients with acute myeloid leukemia, particularly those who are ineligible for transplant, can be critical to treatment outcomes and quality of life for patients. In this episode, CANCER BUZZ speaks with Thomas LeBlanc, MD, hematologic oncologist, associate professor of Medicine, and associate professor in Population Health Sciences at Duke Cancer Institute, about the importance of keeping patients with acute myeloid leukemia in first remission as long as possible through maintenance therapy.   “You have to be aware of the benefits of maintenance therapy…and for patients who are being considered for transplant but who do not end up getting a transplant, it should really be the default option that those patients receive a maintenance therapy.” –Thomas W. LeBlanc, MD   Guest:         Thomas W. LeBlanc, MD Hematologic Oncologist, Associate Professor of Medicine, Associate Professor in Population Health Sciences Duke Cancer Network, Duke Cancer Institute Durham, North Carolina   This is the fourth and final episode of a four-part series developed in connection with the ACCC education program Achieving and Maintaining Better Outcomes for Patients with Acute Myeloid Leukemia. This episode was made possible with support by Bristol Myers-Squibb.   Additional Reading/Sources Improving Care Delivery for Transplant-Ineligible Patients with AML AML Care Coordination in the Community Setting [Video Podcast] Critical Conversation Strategies for Patients with AML [Video Podcast] Strategies to Addressing Disparities in Patients with AML [Video Podcast] Shared Decision-making in Acute Myeloid Leukemia Achieving and Maintaining Better Outcomes for Patients with AML Talking about Acute Myeloid Leukemia (Cancer Support Community) Shared Decision-making: Practical Implementation for the Oncology Team (ACCC)

We are so thrilled to be starting season 8 of the Lighthouse Podcast! First and Foremost, we wanted to make you aware that our posting schedule is changing slightly. For this season, new episodes will drop on the first Tuesday of each month. We encourage you to go back and listen to the helpful episodes from Season 1 to 7.   Now, let us introduce you to our guests for the first episode of this season - high school sweethearts - Zach and Karli Lansdell. The Lansdell's currently reside in Rome, GA, and have one outdoor-loving, huge heart, and all-boy named Levi. Their journey with childhood cancer began when Levi was diagnosed with Acute Myeloid Leukemia on August 10, 2022. The journey was long and intense, as they spent over 200 days in the hospital. They did amazing things to make the hospital feel like home and keep Levi comfortable and happy. They have now moved into the post-treatment plan, and that brings its own challenges. Through their journey, they learned to advocate with gut feelings, ask for help, and be honest with your mental health. Both Zach and Karli leave us with some encouraging advice that can be taken to heart right away. In the opener, Chris and Christy mentioned that our retreat applications are open for both families walking through childhood cancer and volunteers. You can learn more by visiting our website at www.lighthousefamilyretreat.org

Join Forbes Riley in a groundbreaking episode featuring Dr. Buck Parker, a seasoned General & Trauma Surgeon turned entrepreneur, and Fay Bunnell, a holistic RN diagnosed with Acute Myeloid Leukemia. Discover their journeys, insights into holistic health, and the revolutionary Nexqloud decentralized cloud computing service.

Join Forbes Riley in a groundbreaking episode featuring Dr. Buck Parker, a seasoned General & Trauma Surgeon turned entrepreneur, and Fay Bunnell, a holistic RN diagnosed with Acute Myeloid Leukemia. Discover their journeys, insights into holistic health, and the revolutionary Nexqloud decentralized cloud computing service.

In this captivating episode, join Dr. Julian Gold, a 30-year physician and former mayor of Beverly Hills, as he shares his inspiring journey of battling Acute Myeloid Leukemia. From being a respected medical professional to becoming a patient, Dr. Gold had to navigate the challenges of his diagnosis and treatment. He emphasizes the importance of staying positive and focusing on recovery, while also shedding light on the role of caregivers, family, and community support. Discover Dr. Gold's daily rules of recovery and gain valuable insights into life after treatment.

Becca Boylan, a fifth generation Montanan, recently completed a 475 miles run across her home state to share the story of her mother's fight against Acute Myeloid Leukemia. The inspiration for the run came after Becca's experience helping her mother fight the disease for the past year and using running as a way to "metabolize" the emotions she was going through.Through the metaphor of running, Becca, the oldest of six kids, hoped to show others that we are capable of far more than we think possible and we hold the strength we need to face any of life's challenges, whether it's a cancer diagnosis or a mountain marathon. Instagram: @beccaboylanThe Montana Run Website: https://gamma.app/docs/Join-The-Montana-RunSponsor Messages:Roark The best travel gear isn't born in a factory, it's inspired by journeys taken by real people exploring the world. Their team pulls design inspiration straight from the cultures and climates of new destinations to create clothing and gear tailored for travel and adventure sports. For a limited time, as one of our listeners, you can get 15% off your first order! Just go to roark.com and use promo code ASP15 at checkout Visit Yosemite Yosemite is by far my favorite place in the world! I would love for every Adventure Sports Podcast listener to go there and see why I'm always talking about it. You can get started on your own adventure at TravelYosemite.com. Wonderul PistachiosThe key to any good adventure, big or small, is having great snacks. Keep yourself full and focused on all summer adventures, from dropping the kiddos off at camp, to running between meetings with Wonderful Pistachios They come in a variety of flavors and sizes, perfect for enjoying with family and friends or taking them with you on the go. Unlike meat, protein-powered pistachios are naturally cholesterol-free and add fiber to your day. Visit WonderfulPistachios.com to learn more.Better HelpThis episode is sponsored by/brought to you by BetterHelp. Give online therapy a try at betterhelp.com/ADVENTURESPORTS and get on your way to being your best self.Green ChefGreen Chef delivers everything you need to cook delicious dinners at home. We send seasonal organic ingredients and chef-crafted recipes right to your doorstep. Ingredients come pre-portioned and prepped, saving time. Our recipes are so easy to prepare, anyone can do it—yes, even if you can't make toast. Green Chef offers meal plans for all tastes, from paleo to vegan, and more.Website: https://www.greenchef.comOur Sponsors:* Check out Green Chef and use my code asp250 for a great deal: https://www.greenchef.com/asp250* Check out Oris Watches: https://www.oris.ch* Check out Roark and use my code ASP15 for a great deal: https://roark.com/* Check out Shopify and use my code asp for a great deal: https://www.shopify.com/aspSupport this podcast at — https://redcircle.com/adventure-sports-podcast/donationsAdvertising Inquiries: https://redcircle.com/brandsPrivacy & Opt-Out: https://redcircle.com/privacy